Bladder cancer: open trials in Netherlands

34 open trials have a site in Netherlands. Registry data; only the trial team decides who can take part.

NCT05614739
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Trial Treatment · Phase 1 · Eli Lilly and Company
Erasmus MC, GE Rotterdam
Registry updated 2026-11-04
NCT06919965
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Canisius Wilhelmina Ziekenhuis, Nijmegen · Radboud universitair medisch centrum Stichting, Nijmegen · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam · Universitair Medisch Centrum Utrecht, Utrecht
Registry updated 2026-11-03
NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Academisch Ziekenhuis Maastricht, Maastricht · Sint Antonius Ziekenhuis Stichting, Nieuwegein · Radboud universitair medisch centrum Stichting, Nijmegen · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam · Stichting Elisabeth-TweeSteden Ziekenhuis, Tilburg · Isala Klinieken Stichting, Zwolle
Registry updated 2026-11-03
2024-516906-47-00
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
Trial Treatment · Phase 2/3 · Daiichi Sankyo Inc.
Amsterdam UMC, locatie AMC, Amsterdam · Maastricht University Medical Center+ (MUMC+), Maastricht · Radboud universitair medisch centrum Stichting, Nijmegen · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam · Universitair Medisch Centrum Utrecht, Utrecht
Registry updated 2026-10-29
NCT07222488
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam
Registry updated 2026-10-29
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Trial Treatment · Phase 2 · Daiichi Sankyo
Amsterdam UMC Locatie VUMC, Amsterdam · Universitair Medisch Centrum Groningen, Groningen · Leids Universitair Medisch Centrum, Leiden · Maastricht University Medical Center, Maastricht · Radboud University Medical Center, Nijmegen
Registry updated 2026-10-26
NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Trial Treatment · Phase 1/2 · Daiichi Sankyo
Amsterdam UMC Stichting, Amsterdam · Universitair Medisch Centrum Groningen, Groningen · Radboud Universitair Medisch Centrum (Radboudumc), Nijmegen · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam · Universitair Medisch Centrum Utrecht, Utrecht
Registry updated 2026-10-26
NCT06960577
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Trial Treatment · Phase 2 · AstraZeneca
Netherlands Cancer Institute, Amsterdam · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam
Registry updated 2026-10-08
NCT07218380
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Trial Treatment · Phase 3 · Eli Lilly and Company
Amsterdam UMC Locatie VUMC, Amsterdam · Amphia Ziekenhuis - Locatie Breda Molengracht, Breda · Radboudumc, Nijmegen · Erasmus Medisch Centrum, Rotterdam
Registry updated 2026-10-07
2026-525965-29-00
A study investigating whether it is possible to preserve the bladder in participants with bladder cancer by starting with the drugs enfortumab vedotin plus pembrolizumab, followed by further treatment of the bladder depending on the effect on the bladder tumor: FIDELIO
Trial Treatment · Phase 2 · Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Leids Universitair Medisch Centrum (LUMC), Leiden · Universitair Medisch Centrum Utrecht, Utrecht
Registry updated 2026-10-05
NCT02969083
Feasibility study of Neo-adjuvant (before surgery) versus Adjuvant (after surgery) chemotherapy in Upper Tract Urothelial Carcinoma
Trial Treatment · Phase 2 · European Uro-Oncology Group Stichting
Academisch Medisch Centrum, Amsterdam · Leids Universitair Medisch Centrum (LUMC), Leiden · Canisius Wilhelmina Ziekenhuis, Nijmegen · Radboud Universitair Medisch Centrum (Radboudumc), Nijmegen
Registry updated 2026-10-05
NCT07232602
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam
Registry updated 2026-10-02
NCT06833073
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Rijnstate Ziekenhuis Stichting, Arnhem · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam
Registry updated 2026-10-01
NCT05562830
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Academisch Ziekenhuis Maastricht, Maastricht · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam
Registry updated 2026-09-28
NCT04503577
Prospective Bladder Cancer Infrastructure (ProBCI)
Research · Prospective Bladder Cancer Infrastructure Foundation
ZGT, Almelo · Meander Medical Center, Amersfoort · Amsterdam UMC location VUmc, Amsterdam · Rijnstate, Arnhem · Amphia Ziekenhuis, Breda · Albert Schweitzer Hospital, Dordrecht · Ziekenhuis Gelderse Vallei, Ede · Treant Hospital, Emmen · University Medical Center Groningen, Groningen · Spaarne Gasthuis, Hoofddorp · Medisch Centrum Leeuwarden, Leeuwarden · Alrijne Ziekenhuis, Leiderdorp · Maastricht University Medical Center, Maastricht · Canisius Wilhelmina Ziekenhuis, Nijmegen · Radboud univerisity Medical Center, Nijmegen · Erasmus Medical Center, Rotterdam · Jeroen Bosch Hospital, 's-Hertogenbosch · Zuyderland, Sittard · Elisabeth-Tweesteden Ziekenhuis, Tilburg · University Medical Center Utrecht, Utrecht · VieCuri, Venlo · SKB Winterswijk, Winterswijk · Isala, Zwolle
Registry updated 2026-09-21
NCT06668493
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Trial Treatment · Phase 1/2 · Ferring Pharmaceuticals
Amsterdam UMC Stichting, Amsterdam
Registry updated 2026-09-15
2025-523781-25-00
PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).
Trial Treatment · Phase 1 · CimCure B.V.
Netherlands Cancer Institute, Amsterdam · Amsterdam UMC Stichting, Amsterdam · Leids Universitair Medisch Centrum (LUMC), Leiden · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam
Registry updated 2026-09-14
NCT06253871
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Trial Treatment · Phase 1 · Iambic Therapeutics, Inc
Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam
Registry updated 2026-09-09
NCT06644755
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Trial Treatment · Phase 1 · Daiichi Sankyo
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), Amsterdam
Registry updated 2026-09-04
NCT07782164
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
Research · Amsterdam UMC, location VUmc
Amsterdam UMC, Amsterdam
Registry updated 2026-08-28
NCT07106762
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Trial Treatment · Phase 2/3 · Bristol-Myers Squibb
Amsterdam · Breda · Leeuwarden
Registry updated 2026-07-29
NCT05503797
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Trial Treatment · Phase 2 · Fore Biotherapeutics
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam
Registry updated 2026-07-27
NCT07169734
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Trial Treatment · Phase 1/2 · Alentis Therapeutics AG
The Netherlands Cancer Institute (NKI), Amsterdam · Radboudumc - Centrum voor Oncologie, Nijmegen · Erasmus University Medical Center, Rotterdam
Registry updated 2026-07-02
NCT07663747
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
Trial Treatment · Phase 2 · The Netherlands Cancer Institute
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam · Leiden University Medical Center Leiden (LUMC), Leiden · University Medical Center Utrecht(UMCU), Utrecht
Registry updated 2026-06-25
2024-516870-31-00
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors
Trial Treatment · Phase 1 · Merck Sharp & Dohme LLC
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Radboud universitair medisch centrum Stichting, Nijmegen
Registry updated 2026-05-28

All Bladder cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error